Barclays
BNTC icon

Barclays’s Benitec Biopharma BNTC Stock Holding History

Barclays’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Sell
3,835
-19,376
-83% -$224K ﹤0.01% 4390
2025
Q4 		$313K Buy
23,211
+1,928
+9% +$26.7K ﹤0.01% 4111
2025
Q3 		$299K Sell
21,283
-5,657
-21% -$72.2K ﹤0.01% 4104
2025
Q2 		$315K Buy
+26,940
New +$377K ﹤0.01% 4025
2022
Q3 		– Sell
-8,018
Closed -$158K – 4801
2022
Q2 		$158K Buy
8,018
+4,565
+132% +$106K ﹤0.01% 3559
2022
Q1 		$137K Buy
+3,453
New +$143K ﹤0.01% 3632

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Barclays's BNTC Position: Q1 2026 in Review

Barclays reduced its Benitec Biopharma (BNTC) stake by 83% in Q1 2026, selling an estimated $224K and leaving 3,835 shares worth $40.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4390.

Barclays first reported a position in BNTC in Q1 2022 and has held it in 6 quarters since. The position peaked at $315K in Q2 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Barclays held 3,835 shares of Benitec Biopharma worth $40.8K as of Q1 2026.
  • Barclays sold 19,376 Benitec Biopharma shares in Q1 2026, an estimated $224K.
  • Benitec Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4390 holding.
  • Barclays first reported a position in Benitec Biopharma in Q1 2022 and has held it in 6 quarters since.
  • Barclays's Benitec Biopharma position peaked at $315K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.